Foghorn Therapeutics (FHTX) Stock: Buy, Sell, or Hold?
FHTX - Foghorn Therapeutics Inc. Common Stock
$2.02
-0.90 (-30.82%)
▼
5d:
-42.29%
30d:
-60.93%
90d:
-60.0%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When FHTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: FHTX is down 42.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: FHTX is down 42.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: FHTX is currently trading at $2.02, which is considered oversold relative to its 30-day fair value range of $3.44 to $5.76.
Technical Outlook: Technically, FHTX is showing sideways momentum. Immediate support is located at $1.79, while resistance sits at $4.32. Short-term momentum is weak, with the stock down 30.8% recently.
Market Sentiment: FHTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.89 (+389.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FHTX is showing sideways momentum. Immediate support is located at $1.79, while resistance sits at $4.32. Short-term momentum is weak, with the stock down 30.8% recently.
Market Sentiment: FHTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.89 (+389.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.44 -
$5.76
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-30.8%)
- BULLISH: Trading 389.5% below Wall St target ($9.89)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.44 -
$5.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.79
Resistance Level
$4.32
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.84
Wall Street Target
$9.89
(+389.5%)
Revenue Growth (YoY)
112.7%
Profit Margin
-175.8%
Share & Embed Analysis
Last updated: October 03, 2026 3:08 AM ET
Data refreshes hourly during market hours. Next update: 4:08 AM
Data refreshes hourly during market hours. Next update: 4:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FHTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 55 HOLD |
